Side-effects of anti-inflammatory steroids could be prevented, research finds

(Medical Xpress)—Problem side effects including high blood pressure, obesity, muscle wasting, osteoporosis and skin thinning in arthritis and asthma sufferers who take a certain kind of steroid could be prevented by deleting a key gene, researchers at the University of Birmingham have discovered.

The can affect anyone who takes , which can also include the recipients of , who take them to prevent the organ being rejected.

The Birmingham research, published online in Proceedings of the National Academy of Science (PNAS), demonstrates that the side effects associated with glucocorticoid use are prevented in mice when the gene for an enzyme called 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is deleted. This raises the possibility of the same effect occurring in humans.

Dr Gareth Lavery, from the School of Clinical and Experimental Medicine at the University of Birmingham said: "Our findings identify a link between the side-effects experienced by people taking prescribed glucocorticoids, and the gene 11β-HSD1 – raising the exciting possibility of using selective 11β-HSD1 inhibitors as an adjunctive therapy to reduce the side-effect profile associated with long-term glucocorticoid use."

This enzyme generates glucocorticoids, within cells and organs including fat, liver, skin and muscle. The team have shown that the side-effects associated with therapeutic glucocorticoid use are driven by an 11β-HSD1-affected increase of glucocorticoid levels in these tissues. By deleting the 11β-HSD1 gene from a group of mice, the researchers found that the negative effects the glucocorticoid treatments were abolished. These findings extend previous observations made by the team in which a patient with defective 11β-HSD1 activity was protected from the adverse effects associated with prolonged high glucocorticoid exposure.

More information: Stuart A. Morgan, Emma L. McCabe, Laura L. Gathercole, Zaki K. Hassan-Smith, Dean P. Larner, Iwona J. Bujalska, Paul M. Stewart, Jeremy W. Tomlinson, and Gareth G. Lavery. "11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess." PNAS 2014 ; published ahead of print June 2, 2014, DOI: 10.1073/pnas.1323681111

add to favorites email to friend print save as pdf

Related Stories

Designing safer glucocorticoid drugs

Dec 01, 2010

Glucocorticoid drugs are used widely to treat numerous conditions, including rheumatoid arthritis, allergic reactions, asthma, and some forms of cancer, and transplant recipients.

Novel diabetes hope comes from Chinese herbs

Aug 17, 2010

Emodin, a natural product that can be extracted from various Chinese herbs including Rheum palmatum and Polygonum cuspidatum, shows promise as an agent that could reduce the impact of type 2 diabetes. Findings published in ...

'Intelligent medicine' erases side effects

May 31, 2012

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data ...

Recommended for you

Asthma risk varies with ethnic ancestry among Latinos

Oct 07, 2014

Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom ...

Asthma vaccine discovery

Oct 06, 2014

With asthma now affecting up to one in four New Zealand children, the researchers say this is a promising step in the challenge to understand and control asthma.

Phthalates heighten risk for childhood asthma

Sep 17, 2014

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

User comments